Comparison of Presbyopia Between Glaucoma Patients Using Prostaglandin F Receptor Agonists and Fixed Combination Therapy.

Objective: The purpose of this study was to compare the near add power among glaucoma patients using prostaglandin F (FP) receptor agonists and fixed combination therapies and controls.

Methods: Participants were aged from 40 to 69 years and phakic with visual acuity of 20/25 or better, and included 2200 controls, 784 patients using FP receptor agonist for primary open-angle glaucoma (FP), and 412 patients using fixed combination (Combi). Each group was further divided into three groups based on age: those aged 40 to 49 years (40s), those aged 50 to 59 years (50s), and those aged 60 to 69 years (60s), and the near add power at 30 cm and various ophthalmic factors were compared.

Results: The mean near add power for the control, FP, and Fixed combination groups were 1.21±0.66, 1.88±0.75 and 2.04±0.81 for those in their 40s, 2.16±0.59, 2.48±0.55 and 2.70±0.53 for those in their 50s, and 2.74±0.38, 2.89±0.35 and 2.97±0.17 for those in their 60s, respectively. Significant differences were found between all pairs of groups in all age groups (P<0.05, t-test). The odds ratios for near add power reaching 3.00 D were 4.8 (95% CI, 4.0-5.7) for glaucoma, 2.5 (2.1-3.0) for FP, and 6.0 (4.7-7.9) for the Fixed combination group, all of which were significant.

Conclusion: The mean near add power of the Fixed combination group was higher than that of the control and FP groups for the same ages, indicating a faster progression of presbyopia.